Synthesis and biological activities of novel 4″-alkylidene avermectin derivatives

Bioorganic and Medicinal Chemistry Letters

Volumn 13, Issue 22, 2003, Pages 3943-3946

  Nagai, Kenichiro ^a   Sunazuka, Toshiaki ^a   Shiomi, Kazuro ^a   Harder, Achim ^b   Turberg, Andreas ^b   Omura, Satoshi ^a  

^a KITASATO UNIVERSITY   (Japan)

^b BAYER AG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHELMINTIC AGENT; ANTIPARASITIC AGENT; AVERMECTIN DERIVATIVE; PHOSPHORUS DERIVATIVE;

ANTIMICROBIAL ACTIVITY; ARTEMIA; ARTEMIA SALINA; ARTICLE; CAENORHABDITIS ELEGANS; CONTROLLED STUDY; DRUG CONFORMATION; DRUG POTENCY; DRUG SYNTHESIS; HORNER WADSWORTH EMMONS REACTION; NONHUMAN;

ARTEMIA SALINA; CAENORHABDITIS; CAENORHABDITIS ELEGANS; SALINA;

EID: 0242285612     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2003.09.003     Document Type: Article

References (23)

1. (a) Burg H.R., Miller B.M., Baker E.E., Birnbaum J., Currie S.A., Hartman R., Kong Y.-L., Monaghan R.L., Olson G., Putter I., Tunac J.B., Wallick H., Stapley E.O., Oiwa R., Ōmura S. Antimicrob. Agents. Chemother. 15:1979;361 (b) Fisher M.H., Mrozik H. Ōmura S. Macrolide Antibiotics: Chemistry, Biology, and Practice. 1984;553-606 Academic, New York.
2. (a) Burg H.R., Miller B.M., Baker E.E., Birnbaum J., Currie S.A., Hartman R., Kong Y.-L., Monaghan R.L., Olson G., Putter I., Tunac J.B., Wallick H., Stapley E.O., Oiwa R., Ōmura S. Antimicrob. Agents. Chemother. 15:1979;361 (b) Fisher M.H., Mrozik H. Ōmura S. Macrolide Antibiotics: Chemistry, Biology, and Practice. 1984;553-606 Academic, New York.
3. Dybas R.A. Campbell W.C. Ivermectin and Abamectin. 1989;287-310 Springer-Verlag, New York.
4. Avermectin B1 consists of 80% a-component and 20% b-component. The b component has an isopropyl group at the 25 position.
5. Chabala J.C., Mrozik H., Tolman R.L., Eskola P., Lusi A., Peterson L.H., Woods M.F., Fisher M.H., Campbell W.C. J. Med. Chem. 23:1980;1134.
6. Greene B.M., Brown K.R., Taylor H.R. Campbell W.C. Ivermectin and Abamectin. 1989;311-323 Springer-Verlag, New York.
7. Zaha O., Hirata T., Kinjo F., Saito A., Fukuhara H. J. Infect. Chemother. 8:2002;94.
8. Richard-Lenoble D., Chandenier J., Gaxotte P. Fundam. Clin. Pharmacol. 17:2003;199.
9. (a) Davies H.G., Green R.H. Chem. Soc. Rev. 20:1991;211.
10. (b) Davies H.G., Green R.H. Chem. Soc. Rev. 20:1991;271.
11. (c) Sunazuka T., Omura S., Iwasaki S., Ōmura S. Ōmura S. Macrolide Antibiotics: Chemistry, Biology, and Practice. 2nd edn:2002;99-180 Academic Press, New York.
12. (a) Mrozik H., Eskola P., Fisher M.H., Egerton J.R., Cifelli S., Ostilind D.A. J. Med. Chem. 25:1982;658.
13. (b) Meinke P.T., O'Connor S.P., Shoop W.L., Fisher M.H., Mrozik H. Bioorg. Med. Chem. Lett. 3:1993;2675.
14. (c) Mrozik H., Eskola P., Arison B.H., Linn B.O., Lusi A., Matzuk A., Shih T.L., Tischler M., Waksmunski F.S., Wyvratt M.J., Blizzard T.A., Margiatto G.M., Fisher M.H., Shoop W.L., Egerton J.R. Bioorg. Med. Chem. Lett. 5:1995;2435.
15. (a) Mrozik H., Eskola P., Fisher M.H., Egerton J.R., Cifelli S., Ostilind D.A. J. Med. Chem. 25:1982;658 (b) Meinke P.T., O'Connor S.P., Shoop W.L., Fisher M.H., Mrozik H. Bioorg. Med. Chem. Lett. 3:1993;2675 (c) Mrozik H., Eskola P., Arison B.H., Linn B.O., Lusi A., Matzuk A., Shih T.L., Tischler M., Waksmunski F.S., Wyvratt M.J., Blizzard T.A., Margiatto G.M., Fisher M.H., Shoop W.L., Egerton J.R. Bioorg. Med. Chem. Lett. 5:1995;2435 (d) Meinke P.T., Shoop W.L., Michael B.F., Blizzard T.A., Dawson G.R., Fisher M.H., Mrozik H. Bioorg. Med. Chem. Lett. 8:1998;3643.
16. Kok L.T., Lasota J.A., McAvoy T.J., Dybas R.A. J. Econ. Entomol. 89:1996;63.
17. Shoop W.L., Egerton J.R., Eary C.H., Haines H.W., Michael B.F., Mrozik H., Eskola P., Fisher M.H., Slayton L., Ostlind D.A., Skelly B.J., Fulton R.K., Barth D., Costa S., Gregory L.M., Campbell W.C., Seward R.L., Turner M.J. Int. J. Parasitol. 26:1996;1237.
18. 4 and concentrated in vacuo. The crude product was purified by preparative TLC (toluene-ethyl acetate=2:1) to provide 5E (64.5 mg, 79%) and 5Z (17.6 mg, 21%) as a white powder.
19. 3) δ (ppm): 173.8, 161.8, 139.6, 138.0 (×2), 136.2, 135.1, 127.7, 124.7, 120.3, 118.3, 118.0, 116.0, 96.9, 95.7, 95.0, 92.8, 82.0, 81.0, 80.4, 79.1, 79.0, 76.9, 74.9, 68.4, 68.3 (×2), 67.7, 67.4, 67.1, 56.9, 56.7, 45.7, 40.4, 39.7, 38.6, 36.6, 35.1, 34.5, 34.2, 30.5, 27.4, 20.2, 19.9, 18.4, 18.2, 16.3, 15.1, 12.9, 12.0.
20. The E/Z configuration of nitriles (5) was determined by NOESY experiments.
21. Cvetovich R.J., Kelly D.H., DiMichele L.M., Shuman R.F., Grabowski E.J. J. Org. Chem. 59:1994;7704.
22. Blizzard A.T., Margiatto G.M., Mrozik H., Shoop W.L., Frankshun R.A., Fisher M.H. J. Med. Chem. 35:1992;3873.
23. Enomoto Y., Shiomi K., Matsumoto A., Takahashi Y., Iwai Y., Harder A., Kolbl H., Woodruff H.B., Ōmura S. J. Antibiot. 54:2001;308.